针对与肥胖相关的HFpEF新型受控代谢加速器:HuMAIN-HFpEF随机临床试验
Ambarish Pandey1, Gregory D Lewis2, Barry A Borlaug3
1Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
JAMA cardiology
|March 12, 2025
概括
HU6,一种代谢加速剂,在患有与肥胖相关的心力衰竭患者中显著降低体重和脂肪量,并保留排泄分数 (HFpEF). 需要进一步的研究来评估对运动功能和心血管结果的长期益处.
科学领域:
- 心脏病学和新陈代谢健康
- 药理学和治疗学 药理学和治疗学
背景情况:
- 过多的体脂是心力衰竭发展的关键因素,其中包括心力衰竭与保存的喷射分数 (HFpEF).
- HU6是一种新型的代谢加速器,旨在通过线粒体脱来增加新陈代谢并促进脂肪损失.
研究的目的:
- 评估HU6在减轻体重,改善心肺呼吸能力 (峰值VO2) 和改变与肥胖相关的HFpEF患者的身体组成方面的疗效和安全性.
- 评估HU6对该群体关键临床标志物和患者报告结果的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制,剂量升级的2A期试验 (HuMAIN-HFpEF) 涉及慢性稳定HFpEF和肥胖症患者.
- 参与者接受HU6 (150-450毫克/天) 或安慰剂治疗19周,主要终点是体重变化.
主要成果:
- 与安慰剂相比,HU6治疗导致体重 (2.86公斤),总脂肪量 (2.96公斤) 和内脏脂肪百分比 (1.3%) 在统计学上显著减少.
- 没有观察到肌肉质量的显著损失. 峰值VO2,6分钟的步行距离和其他二次临床结果没有显示出统计学上显著的改善.
- 不良事件在各组之间是相似的,严重的不良事件被认为与治疗无关.
结论:
- 在患有与肥胖相关的HFpEF的患者中,HU6在19周内表现出适度但显著的体重减轻,而不会影响肌肉质量.
- 虽然HU6在本试验中没有改善VO2峰值,但需要进行更大,更长时间的研究来确定其改善运动能力,生活质量和心血管结果的潜力.
相关概念视频
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K